|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Covidien plc (COV) Completes Acquisition of CV Ingenuity
1/11/2013 9:05:47 AM
DUBLIN--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of CV Ingenuity. Financial terms of the transaction were not disclosed. CV Ingenuity’s core technology, still in the investigational phase, is a Drug Coated Balloon (DCB) platform with a novel, proprietary, tunable, rapid-release system. “We are pleased to add both the talented team members at CV Ingenuity as well as their promising DCB technology to our growing portfolio of vascular products,” said Stacy Enxing Seng, President, Vascular Therapies, Covidien. “We are committed to being the clear first choice for our physician and hospital partners by delivering technology to improve patient outcomes.”
|
|
|
|
|
|
|
|
|
|
|